Literature DB >> 21686416

Histopathological findings after retinal endovascular lysis in central retinal vein occlusion.

Nicolas Feltgen1, Hansjuergen Agostini, Claudia Auw-Haedrich, Lutz L Hansen.   

Abstract

This case study explores the histopathological findings 9 months after retinal endovascular lysis (REVL) in a 62-year-old woman having a 7-week-old, highly ischaemic central retinal vein occlusion (CRVO) with hand movement vision. Angiographic examination 3 days postoperatively did not show improved arteriovenous passage time. In addition, the patient's postoperative vision did not change, and despite intensive photocoagulation and cryotherapy in the early postoperative period, the globe had to be removed 9 months later because of painful phthisis. Histological findings at the site of puncture were epiretinal membrane, interrupted internal limiting membrane and thickened venous wall. This is the first case to show the histological changes after surgical REVL in a human eye. In this case, REVL did not prevent neovascular glaucoma despite successful recombinant tissue plasminogen activator (rt-PA) injection in a venous branch close to the papilla. It was concluded that rt-PA injection after 7 weeks of CRVO is too late.

Entities:  

Year:  2009        PMID: 21686416      PMCID: PMC3028989          DOI: 10.1136/bcr.11.2008.1205

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.

Authors:  J N Weiss; L A Bynoe
Journal:  Ophthalmology       Date:  2001-12       Impact factor: 12.079

2.  Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases.

Authors:  W R Green; C C Chan; G M Hutchins; J M Terry
Journal:  Retina       Date:  1981       Impact factor: 4.256

3.  Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons.

Authors:  Leon A Bynoe; Robert K Hutchins; Howard S Lazarus; Mark A Friedberg
Journal:  Retina       Date:  2005 Jul-Aug       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.